MASTERPLAN Trial Ph II (2:1) n=74 Median FU 3.2y Periop chemotherapy ± stereotactic body radiotherapy (SBRT) in high-risk, localised pancreatic ductal adenocarcinoma (PDAC) Absolute recurrence reduction: 31.8 percentage points @1y [52% Vs 20.2%] PFS /OS all pS in favour

ESMO 2026 TMH study Unresectable LAHNSCC Weekly C+P +OMC Vs. DCF Non inferior Low toxicity Higher ORR More conversion to resectability

Tislelizumab Where have we reached so far Glimpse on Drug and Trial Portfolio

NGS testing in HCC Mets 1st Line = No role Prior to 2nd / 3rd Line = Have a Clinical Path in mind. Don't blindly do it for all ESMO / Pan Asia Be realistic, Cautious & Judicious

Pathway Trial Ph II TRIAL 6 qualifying criteria Role of Pembro PFS benefit No OS benefit

Locoregional Therapies in HCC How to choose ? Which Shop to go to ? Know thy weapons and its use Individualise MDT Patient and Tumour factors Mutually narrow down

HCC Vs Intrahepatic Cholangiocarcinoma Typical Vs Atypical Features Clinicians Dilemma !!! When to do Biopsy When not to do Biopsy

ESMO 2026 Key late Breaking Abstracts Atypical EGFR mutation Enozertinib: Birth of Redwood 1 (2027) HERIZON-GEA-01 Her2+ GE Adenocarcinoma Zoci: ES SCLC

Peritoneal Surface Malignancy What non surgical Oncologist needs to know PCI & scoring CC scoring And Brief Overview of Randomised Trials Cancer specific

Metastatic HCC Patient Approach / Goals How to approach in Clinic Initial Assessment Patient Selection on various Factors 1st L / 2 L sequencing Options Dosing / Regimen Trial evidence / efficacy Keynote Toxicities to watch

Oncology / Hematology Specific New US FDA approvals Date wise in 2026 With Indications

US FDA 2026: 47 New Drugs Classified by Medical Specialty

Adjuvant therapy for intermediate-risk oral cancer DOI:10.1016j.oraloncology.2024.106972. Need of the hour is refining postoperative risk assessment in oral cavity cancer, but article does not resolve the controversy.

Extended FU.@Oct 2026 NRG BR002 trial Does Ablating All Metastases Improve Outcomes in Oligometastatic Breast Cancer? N=125 pts Ph 2 Extended FU 57.5months No.diff in PFS / OS

SAFFRON trial ESMO 2026 Osimertinib plus savolitinib after osimertinib resistance in EGFR-mutant NSCLC Phase III trial First Glimpse

Top 5 ESMO Practice Changing Papers

NutriCare vs NutriTool: Critical appraisal of Ph III randomized trial 249 pts with newly diagnosed stage I–IV lung cancer recruited across 4 cancer centres Does Active Nutritional care makeany difference? Complete NutriCare package is not superior to nutrition education alone

IMPT vs IMRT in oropharyngeal cancer DOI: 10.1016/j.esmoop.2026.108602. S Intensity-modulated proton therapy (IMPT) reduces acute severe toxicity compared with intensity-modulated photon radiotherapy (IMRT) but this analysis does not establish superior tumour control or survival

Lets Comapre the 2 trials And then Find why it failed

Treatment of Advanced Biliary Tract Cancer: ASCO Living Guideline, Version 2026.1.0 Immune checkpoint inhibitors (durvalumab or pembrolizumab) with chemotherapy v chemotherapy alone for advanced BTC. 1st L therapy options 2ndL therapy options Targeted Rx Options